Cargando...
Safety profile of dalfampridine extended release in multiple sclerosis: 5-year postmarketing experience in the United States
BACKGROUND: Dalfampridine extended release tablets (dalfampridine-ER; prolonged-, modified, or sustained-release fampridine outside the US), 10 mg twice daily, was approved by the US Food and Drug Administration (FDA) in January 2010 to improve walking in people with multiple sclerosis, as determine...
Gardado en:
| Publicado en: | Drug Healthc Patient Saf |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Dove Medical Press
2015
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4687626/ https://ncbi.nlm.nih.gov/pubmed/26719727 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DHPS.S97113 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|